Iovance Biotherapeutics, Inc.
IOVA
Peringkat dalam Saham
#2785
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Harga Saham
$14.87
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$6.74B
Perubahan (1 hari)
4.64%
Perubahan (1 tahun)
555.03%
Negara
US
Perdagangan Iovance Biotherapeutics, Inc. (IOVA)
Kategori
Healthcare
Rasio P/E untuk Iovance Biotherapeutics, Inc. (IOVA)
Rasio P/E per October 2026 TTM: -19.47
Menurut laporan keuangan dan harga saham terbaru dari Iovance Biotherapeutics, Inc., rasio P/E saat ini (TTM) adalah -19.47. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar -4.31.
Riwayat rasio P/E untuk Iovance Biotherapeutics, Inc. dari 2008 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | -19.47 | 237.95% |
| 2024 | -5.76 | 33.88% |
| 2023 | -4.31 | 67.47% |
| 2022 | -2.57 | -69.96% |
| 2021 | -8.56 | -65.39% |
| 2020 | -24.72 | 41.90% |
| 2019 | -17.42 | 150.08% |
| 2018 | -6.97 | 22.88% |
| 2017 | -5.67 | -21.93% |
| 2016 | -7.26 | -41.41% |
| 2015 | -12.40 | -24.14% |
| 2014 | -16.34 | 304.54% |
| 2013 | -4.04 | -23.95% |
| 2012 | -5.31 | 79.73% |
| 2011 | -2.95 | -94.17% |
| 2010 | -50.72 | -99.21% |
| 2009 | -6.45K | 176.01% |
| 2008 | -2.34K | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | -247.86% |
US
|
|
| -28.36 | 45.68% |
US
|
|
| -24.57 | 26.21% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -255.81% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.